亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

医学 阿扎胞苷 内科学 骨髓增生异常综合症 慢性粒单核细胞白血病 低甲基化剂 肿瘤科 髓样 临床终点 白细胞介素-3受体 髓系白血病 微小残留病 白血病 癸他滨 胃肠病学 免疫学 骨髓 临床试验 生物 生物化学 基因表达 基因 DNA甲基化
作者
Daniel Nguyen,Farhad Ravandi,Sa A. Wang,Jeffrey L. Jorgensen,Wei Wang,Kelly S. Chien,Guillermo Montalbán‐Bravo,Ghayas C. Issa,Abhishek Maiti,Yesid Alvarado Valero,Naval Daver,Courtney D. DiNardo,Elias Jabbour,Tapan M. Kadia,Naveen Pemmaraju,Musa Yılmaz,Jae‐Hyun Lee,Pavan Bachireddy,Uday Popat,Guillermo García‐Manero,Hagop M. Kantarjian,Nicholas J. Short
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 322-322 被引量:2
标识
DOI:10.1182/blood-2023-190693
摘要

Background Leukemic stem cells have high expression of CD123 compared to normal hematopoietic stem cells and is therefore a therapeutic target in multiple leukemias including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). Vibecotamab (formally XmAb14045) is a CD3-CD123 bispecific engaging antibody that has shown clinical activity in relapsed/refractory AML, particularly in low-blast disease. We therefore sought to evaluate vibecotamab in other low-blast states, including MDS or CMML after hypomethylating agent failure and MRD-positive AML. Methods In this two-arm, open-label, phase II study, adults with either MDS (IPSS-R intermediate or higher risk) or CMML (CMML-1 or CMML-2) after failure of hypomethylating agents or AML in first or second morphologic remission with detectable MRD at a level of ≥0.1% by flow cytometry were eligible. CD123 expression ≥20% on aberrant myeloid blasts was required for enrollment. Vibecotamab was given IV in a ramp-up dose schedule on days 1 (0.43µg/kg), 3 (0.75µg/kg), 5 (1.1µg/kg), and 8 (1.7µg/kg) in cycle 1, followed by weekly doses of vibecotamab at a dose of 1.7µg/kg. Patients (pts) received up to 4 cycles of vibecotamab in 28-day cycles. The primary endpoint of the MDS/CMML cohort was response rate (CR + mCR + PR + HI + clinical benefit) within 4 cycles. The primary endpoint of the AML MRD cohort was the MRD negativity rate within 4 cycles. Results Between May 2022 and July 2023, 23 pts were treated (11 MDS/CMML, 12 AML MRD). Baseline characteristics are shown in Table 1. In the MDS/CMML cohort, 7 pts (63%) had received two or more prior lines of therapy, 8 pts (73%) had prior venetoclax exposure, and 2 pts (18%) had prior hematopoietic stem cell transplant (HSCT). Six MDS pts (66%) were IPSS-R high or very high risk. In the AML cohort, 6 pts (50%) had received two or more lines of prior therapy, 11 pts (92%) had prior venetoclax exposure, and 5 pts (42%) had prior HSCT. Ten pts (83%) were ELN 2022 adverse risk. The baseline CD123 expression was 72% (range, 43%-99%) in the MDS/CMML cohort and 89% (range, 55%-99%) in the AML MRD cohort. The baseline MRD by flow cytometry in the AML MRD cohort was 1.1% (range, 0.1%-3.9%). Responses are shown in Table 2. In the MDS/CMML cohort, 7 pts responded (64%), with 6 pts (56%) achieving marrow complete remission (mCR) and 1 pt (9%) achieving hematologic improvement (HI) per International Working Group (IWG) 2006 criteria. Among the 9 MDS pts, 4 (44%) achieved mCR + HI (2 HI-N, 1 HI-P, and 1 HI-P + HI-N), and 1 (11%) achieved HI (HI-N + HI-P). Per revised IWG 2023 MDS response criteria, 5 of the 9 MDS pts (56%) achieved complete remission with limited count recovery (CR L). Two of 4 MDS pts (50%) with TP53 mutations achieved CR L. Both CMML pts achieved mCR, with one pt also achieving HI-N. Among 9 pts with baseline bone marrow blasts =>5% at trial enrollment, 6 (67%) achieved a mCR, with or without HI. Best response occurred after the first cycle in all pts. CD123 expression was not associated with likelihood of response. Of the 7 responders, 5 are in ongoing response (range 0.3-6.9 months), one died in CR L from non-hematologic complications (heart failure), and one relapsed 5 months after achieving CR L. Of the 12 pts in the AML MRD cohort, 3 (25%) achieved MRD negativity, all of which occurred after 1 cycle of vibecotamab. Among the 3 responders, all were ELN adverse risk and had prior venetoclax exposure, 2 had prior HSCT, and 1 had inv(3). The median MRD and CD123 expression in responders was 0.2% (range 0.1%-0.2%) and 98% (range 95%-99%) vs 1.8% (range 0.5%-3.9%) and 87% (range 66%-96%) in non-responders, respectively. At last follow-up, all 3 responders are still in MRD-negative remission (range 3.2-12.8 months). Vibecotamab was well-tolerated with no pts requiring dose reductions or being taken off study due to adverse events. Ten pts (44%) experienced grade 2 infusion reactions and 1 pt (4%) experienced a grade 3 infusion reaction. Myelosuppression was minimal, consistent with previous studies of vibecotamab. Conclusion Vibecotamab was safe and active in low-blast, high-risk myeloid diseases, with a response rate of 64% in MDS/CMML after HMA failure and 25% in MRD-positive AML. The clinical activity of vibecotamab, including in pts with prior venetoclax exposure and/or HSCT, and its lack of clinically significant myelosuppression provide rationale to combine it with other agents in AML, MDS, and CMML.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
香蕉觅云的应助被阿九采纳,获得10
2秒前
3秒前
4秒前
joejoe完成签到,获得积分10
7秒前
8秒前
10秒前
10秒前
chuchu7613完成签到,获得积分20
15秒前
24秒前
阿九完成签到,获得积分10
24秒前
兔鸟完成签到 ,获得积分10
25秒前
27秒前
阿九发布了新的文献求助10
27秒前
灵巧绿海完成签到,获得积分10
28秒前
xixi完成签到 ,获得积分10
30秒前
37秒前
42秒前
大胆醉卉完成签到,获得积分10
43秒前
43秒前
科研通AI6.2的应助被weako采纳,获得30
44秒前
科研通AI6.4的应助被weako采纳,获得30
44秒前
生动琦完成签到,获得积分10
45秒前
生动的电脑完成签到,获得积分10
45秒前
zsp完成签到,获得积分10
47秒前
pcs发布了新的文献求助10
48秒前
昨日晚晴完成签到 ,获得积分10
49秒前
51秒前
感存算完成签到,获得积分10
52秒前
54秒前
fantasy的应助被科研通管家采纳,获得10
54秒前
研友_LwlNdn的应助被科研通管家采纳,获得10
54秒前
隐形曼青的应助被Un1que采纳,获得10
55秒前
59秒前
王乐安完成签到,获得积分10
1分钟前
坦率的邑完成签到 ,获得积分10
1分钟前
TFoCR7发布了新的文献求助10
1分钟前
神勇的半芹完成签到,获得积分10
1分钟前
1分钟前
1分钟前
尘路遐远发布了新的文献求助200
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179795
求助须知:如何正确求助?哪些是违规求助? 9570000
关于积分的说明 21808049
捐赠科研通 7775402
什么是DOI,文献DOI怎么找? 3433137
关于科研通互助平台的介绍 2557199
邀请新用户注册赠送积分活动 2478832